Harmony Biosciences Holdings, Inc.
General ticker "HRMY" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.9B (TTM average)
Harmony Biosciences Holdings, Inc. follows the US Stock Market performance with the rate: 9.9%.
Estimated limits based on current volatility of 1.6%: low 36.36$, high 37.51$
Factors to consider:
- Total employees count: 268 as of 2024
- US accounted for 100.0% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Market acceptance of WAKIX, Regulatory and compliance, Reputation and brand risks, Pandemic risks, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [28.81$, 46.90$]
- 2025-12-31 to 2026-12-31 estimated range: [31.20$, 50.34$]
Financial Metrics affecting the HRMY estimates:
- Positive: with PPE of 13.6 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 26.70 > 18.64
- Positive: 6.82 < Operating cash flow per share per price, % of 11.29
- Negative: negative Industry operating cash flow (median)
- Positive: -4.48 < Investing cash flow per share per price, % of -3.47
- Positive: Return on assets ratio (scaled to [-100,100]) of 12.71 > 6.04
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term HRMY quotes
Long-term HRMY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $437.86MM | $582.02MM | $714.73MM |
| Operating Expenses | $317.67MM | $389.99MM | $523.91MM |
| Operating Income | $120.19MM | $192.03MM | $190.83MM |
| Non-Operating Income | $-15.50MM | $-18.63MM | $0.98MM |
| Interest Expense | $18.80MM | $23.76MM | $17.50MM |
| R&D Expense | $70.89MM | $76.06MM | $145.82MM |
| Income(Loss) | $104.69MM | $173.40MM | $191.80MM |
| Taxes | $-76.78MM | $44.54MM | $46.31MM |
| Profit(Loss)* | $181.47MM | $128.85MM | $145.49MM |
| Stockholders Equity | $402.84MM | $466.99MM | $659.15MM |
| Inventory | $4.30MM | $5.36MM | $7.20MM |
| Assets | $673.87MM | $811.45MM | $999.20MM |
| Operating Cash Flow | $144.47MM | $219.39MM | $219.82MM |
| Capital expenditure | $0.17MM | $0.31MM | $1.15MM |
| Investing Cash Flow | $-141.83MM | $-46.44MM | $-67.48MM |
| Financing Cash Flow | $6.84MM | $-105.55MM | $-11.00MM |
| Earnings Per Share** | $3.07 | $2.17 | $2.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.